The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive ...

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free ...

In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free ...

At a median 28.2 months follow-up, investigator-assessed progression-free survival (PFS) was significantly improved when the vincristine in R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...

SAN DIEGO — Patients with diffuse large B-cell lymphoma (DLBCL) continue to show superior progression-free survival at 5 years with first-line pola-R-CHP compared with the R-CHOP regimen, according to ...

In the POLARIX trial, patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression 2 years after receiving a new drug combination ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the ...

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse ...

Basel, 16 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) ...

After a regulatory scare, Roche can now kick off work on changing nearly 20 years of clinical practice for the treatment of diffuse large B-cell lymphoma (DLBCL). The FDA has signed off on Roche’s ...